FDA Alerts

The US Food and Drug Administration has recently approved a new smart watch that can monitor seizure activity and alert caregivers.

The US Food and Drug Administration has issued a warning regarding the presence of opioid compounds in an unregulated botanical substance.

The US Food and Drug Administration has expanded the indication for a drug for chronic kidney disease to now include certain patients without chronic kidney disease.

The FDA has expanded the indication for a drug formerly approved for the treatment of patients with complicated intra-abdominal infections and complicated urinary tract infections.

The US Food and Drug Administration has approved a new oral liquid therapy for the treatment of Clostridium difficile-associated diarrhea and Staphylococcus aureus-associated enterocolitis.

The US Food and Drug Administration has expanded a 2017 contraindication for opioid-containing cough and cold products, which initially only restricted their use in children younger than 12 years.

The US Food and Drug Administration has approved a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the improvement of glycemic control in adults with type 2 diabetes.

The US Food and Drug Administration has approved a new option to treat dangerously low blood pressure in adult patients with septic or other distributive shock.

The US Food and Drug Administration has approved a new treatment option for patients with open-angle glaucoma or ocular hypertension.

The US Food and Drug Administration recently approved a drug for the treatment of adults with active psoriatic arthritis.